Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Transcranial Photobiomodulation for Bipolar Depression

NCT: NCT07510646 · NOT_YET_RECRUITING

NCT IDNCT07510646
StatusNOT_YET_RECRUITING
Start Date2026-07-01
Completion2027-07-01

Brief Summary

This study the effectiveness and safety of light therapy device targeted at the brain using a wearable device, the Vielight RX Gamma as a treatment for bipolar depression. Up to forty patients with bipolar disorder will be enrolled into the study and will either receive active treatment with the Vielight RX Gamma or sham (inactive device). They will be administered the devices in clinic 5days/week for 6 weeks. Changes in disease symptoms, cognitive function, pain, quality of life and rest EEG changes will be assessed.

Frequently Asked Questions

What is Transcranial Photobiomodulation for Bipolar Depression?

Transcranial Photobiomodulation for Bipolar Depression is a clinical trial registered under NCT07510646. Current status: NOT_YET_RECRUITING.

What is the status of NCT07510646?

The current status of NCT07510646 (Transcranial Photobiomodulation for Bipolar Depression) is: NOT_YET_RECRUITING.

When did Transcranial Photobiomodulation for Bipolar Depression start?

Transcranial Photobiomodulation for Bipolar Depression started on 2026-07-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.